Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs BIO-TECHNE Corp (TECH) Price & Performance

MSTZ is trading at $2.66, up 13.43% today, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. Key financial ratios such as P/E, P/S, and P/B are unavailable, limiting fundamental clarity. The stock's recent mention in ETF Trends (September 15, 2026) highlights its inclusion in leveraged ETF discussions, though this reflects market volatility rather than company-specific news.

The outlook is cautious due to weak technicals and missing fundamental data. Risks include high volatility from leveraged ETF exposure and lack of transparent financials. Investors should seek updated SEC filings for earnings and valuation metrics before considering a position, as current data gaps hinder a reliable assessment of growth or stability.

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.